1st and only VMAT2 inhibitor approved for both TD and HD chorea1




Before you prescribed AUSTEDO for his tardive dyskinesia (TD), he was concerned about people noticing his movements.1

Now expressing
himself is
what moves him

*Symptom control defined as change in AIMS total score observed as early as Week 2 in placebo-controlled studies.5

Mechanism of Action:

VMAT2 inhibition can help regulate dopamine function.6

AIMS, Abnormal Involuntary Movement Scale; HD, Huntington’s disease; VMAT2, vesicular monoamine transporter 2.

REFERENCES: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc. 2. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604. 3. Hauser RA, Barkay H, Fernandez HH, et al. Long-term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: a 3-year, open-label extension study. Front Neurol. 2022;13:773999. doi:10.3389/fneur.2022.773999 4. Marder SR, Singer C, Lindenmayer J-P, et al. A phase 3, 1-year, open-label trial of valbenazine in adults with tardive dyskinesia. J Clin Psychopharmacol. 2019;39(6):620-627. 5. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. 6. Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215-1238.